Primary and secondary prevention of colorectal cancer

Clinical Medicine Insights: Gastroenterology

Volumn 7, Issue , 2014, Pages 33-46

  Tárraga López, Pedro J ^a,b   Solera Albero, Juan ^b   Rodríguez Montes, José Antonio ^c  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; CELECOXIB; CYCLOOXYGENASE 2; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN P53; PYRIDOXINE; ROFECOXIB; SULINDAC;

AGING; ALCOHOL CONSUMPTION; ARTICLE; ASCENDING COLON; CALCIUM INTAKE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CAUSE OF DEATH; CHOLESTEROL DIET; COLORECTAL CANCER; COLORECTAL POLYP; COLORECTAL TUMOR; DAIRY PRODUCT; DESCENDING COLON; DIET; DRINKING BEHAVIOR; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; GEOGRAPHIC DISTRIBUTION; HUMAN; INFORMATION RETRIEVAL; LIFESTYLE; MEAT; MEDLINE; MORBIDITY; NUT; OBESITY; PHYSICAL INACTIVITY; PRIMARY PREVENTION; PROTEIN EXPRESSION; RECTUM; RICE; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SEX DIFFERENCE; SIGMOIDOSCOPY; SMOKING; TUMOR LOCALIZATION; VEGETABLE;

EID: 84904360006     PISSN: None     EISSN: 11795522     Source Type: Journal    
DOI: 10.4137/CGast.S14039     Document Type: Article

References (143)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
2. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transition according to the human development index (2008-2030): a population-based study. Lancet Oncol. 2012;13:790-801.
3. American Cancer Society. Cancer Facts & Figures, 2013. Atlanta, GA: American Cancer Society; 2013.
4. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimated for 40 countries in 2012. Eur J Cancer. 2013;49:1374-1403.
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
6. Cen-ter MM, Jemal A, Ward E. International trends in colorectal cancer incidencerates. Cancer Epidemiol Biomarkers Prev. 2009;18:1688-1694.
7. Cen-ter MM, Jemal A, Smith RA, Ward E. Worldwide variatios in colorectal cancer. CA Cancer J Clin. 2009;59:366-378.
8. Boffetta P, Hazelton WD, Chen Y, et al. Body mass, tobacco smoking, alcohol drinkings and risk of cancer of the small intestine-a pooled analysis of over 500,000 subjects in the Asia Cohort Consortium. Ann Oncol. 2012;23:1894-1898.
9. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573.
10. Vargas AJ, Thompson PA. Diet and nutrient factors in colorectal cancer risk. Nutr Clin Pract. 2012;27:613-623.
11. Su LJ, Arab L. Alcohol consumption and risk of colon cancer: evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up study. Nutr Cancer. 2004;50:111-119.
12. Hu J, La Vecchia C, de Groh M, Negri E, Morrison H, Mery L. Dietary cholesterol intake and cancer. Ann Oncol. 2012;23:491-500.
13. Schernhamer ES, Ogino S, Fuch CS. Folate and vitamin B6 intake and risk of colon cancer in relation to p53 expression. Gastroenterology. 2008;135:770-780.
14. Tantamango YM, Knutsen SF, Beeson WL, Fraser G, Sabate J. Foods and food groups associated with the incidence of colorectal polyps: the Adventist Health Study. Nutr Cancer. 2011;63:565-572.
15. Huncharek M, Muscat J, Kupelnick B. Colorectal cancer risk and dietary intake of calcium, vitamin D, and dairy products: a meta-analysis of 26,335 cases from 60 observational studies. Nutr Cancer. 2009;61:47-69.
16. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008;134:21-28.
17. Ferrari P, Jenab M, Novat T, et al. Lifetime and baseline alcohol intake and risk of colon and rectal cancer in the European prospective investigations into cancer and nutrition (EPIC). Int J Cancer. 2007;121:2065-2072.
18. Boyle P, Levin B, eds. World Cancer Report 2008. Lyon: International Agency for Research on Cancer; 2008.
19. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365-1371.
20. Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med. 1995;123:904-910.
21. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomized controlled trial. Lancet. 2010;375:1624-1633.
22. Weitz J, Koch M, Debus J, Hôhler T, Gall PR, Büchler MW. Colorectal cancer. Lancet. 2005;365:153-165.
23. Winawer SJ, Zauber AG, Verdes H, et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Work group. N Engl J Med. 1996;334:82-87.
24. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol. 2001;96:2992-3003.
25. Lynch KL, Ahnen DJ, Byers T, Weiss DG, Lieberman DA. First-degree relatives of patients with advanced colorectal adenomas have an increased prevalence of colorectal cancer. Clin Gastroenterol Hepatol. 2003;1:96-102.
26. Wingo PA, Jamison PM, Hiatt RA, et al. Building the infrastructure for nationwide cancer surveillance and control-a comparison between the National Program of Cancer Registries (NPGR) and the Survelillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control. 2003;14:175-193.
27. Feig B, Berger D, Furnham G. Oncología Quirúrgica. Madrid: Editorial Marbán Libros SL; 2005:212.
28. Sandhu MS, White IR, McPherson K. Systematic review of the prospective cohort studies on meat consumption and colorectal cancer risk: a meta-analytical approach. Cancer Epidemiol Biomarkers Prev. 2001;10:439-446.
29. Norat T, Lukanova A, Ferrari P, Riboli E. Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer. 2002;98:241-256.
30. Norat T, Lukanova A, Ferrari P, Riboli E. Meat consumption and colorectal cancer risk: an estimate of attributable and preventable fractions. IARC Sci Publ. 2002;156:223-225.
31. Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a metaanalysis of prospective studies. Int J Cancer. 2006;119:2657-2664.
32. Le Marchand L. Meat intake, metabolic genes and colorectal cancer. IARC Sci Publ. 2002;156:481-485.
33. Santarelli RL, Pierre F, Corpet DE. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. Nutr Cancer. 2008;60:131-144.
34. Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr. 2003;78:559S-569S.
35. Park Y, Hunter DJ, Spiegelman D, et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA. 2005; 294:2849-2857.
36. Schatzkin A, Mouw T, Park Y, et al. Dietary fiber and whole-grain consumption in relation to colorectal cancer in the NIH-AARP Diet and Health Study. Am J Clin Nutr. 2007;85:1353-1360.
37. Koushik A, Hunter DJ, Spiegelman D, et al. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst. 2007;99:1471-1483.
38. Asano TK, McLeod RS. Fibra dietética para la prevención de carcinomas y adenomas colorrectales. Oxford: Update Software Ltd; 2008.
39. Jacobs ET, Lanza E, Alberts DS, et al. Fiber, sex, and colorectal adenoma: results of a pooled analysis. Am J Clin Nutr. 2006;83:343-349.
40. Millen AE, Subar AF, Graubard BI, et al. Fruit and vegetable intake and prevalence of colorectal adenoma in a cancer screening trial. Am J Clin Nutr. 2007;86:1754-1764.
41. Norat T, Riboli E. Dairy products and colorectal cancer: a review of possible mechanisms and epidemiological evidence. Eur J Clin Nutr. 2003;57:1-17.
42. Rodrigo L, Riestra S. Diet and colon cancer. Rev Esp Enferm Dig. 2007;99(4): 183-189.
43. Cho E, Smith-Warner SA, Spiegelman D, et al. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst. 2004;96: 1015-1022.
44. Sanjoaquin MA, Allen N, Couto E, Roddam AW, Key TJ. Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer. 2005;113:825-828.
45. Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008; 134:29-38.
46. Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007;297:2351-2359.
47. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006;354: 684-696.
48. Larriba MJ, Valle N, Pálmer HG, et al. The inhibition of Wnt/beta-catenin signalling by 1alfa, 25-dihydroxivitamin D3 is abrogated by Snail1 in human colon cancer cells. (Artículo) Endocrine-Related Cancer. 2007;14:1-12.
49. Ding EL, Mehta S, Fawzi WW, Giovannucci EL. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of women's health initiative randomized trial. Int J Cancer. 2008;122: 1690-1694.
50. Weingarten MA, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev. 2008:CD003548.
51. Gorham ED, Garland CF, Garland FC, et al. Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol. 2005;97:179-194.
52. Gorham ED, Garland CF, Garland FC, et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med. 2007; 32:210-216.
53. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database Syst Rev. 2008:CD004183.
54. Mannisto S, Yaun SS, Hunter DJ, et al. Dietary carotenoidsand risk of colorectal cancer in a pooled analysis of 11 cohort studies. Am J Epidemiol. 2007;165: 246-255.
55. Bjelakovic G, Nagorni A, Nikolova D, Simonetti RG, Bjelakovic M, Gluud C. Meta-analysis: antioxidant supplements for primary and secondary prevention of colorectal adenoma. Aliment Pharmacol Ther. 2006;24:281-291.
56. IARC Working Group on the Evaluation of Cancer-Preventive Agents. Weight control and physical activity. IARC Sci Publ. 2002.
57. Samad AK, Taylor RS, Marshall T, Chapman MA. A meta-analysis of the association of physical activity with reduced risk of colorectal cancer. Colorectal Dis. 2005;7:204-213.
58. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a metaanálisis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 2007;16:2533-2547.
59. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr. 2007;86:556-565.
60. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-578.
61. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98:920-931.
62. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem. 2008;114:63-70.
63. Cho E, Smith-Warner SA, Ritz J, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med. 2004;140:603-613.
64. Moskal A, Norat T, Ferrari P, Riboli E. Alcohol intake and colorectal cancer risk: a dose-response meta-analysis of published cohort studies. Int J Cancer. 2007;120: 664-671.
65. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:725-731.
66. Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: association by tumour type. J Intern Med. 2002;252:206-224.
67. Botteri E, Iodice S, Raimondi S, Maisonneuve P, Lowenfels AB. Cigarette smoking and adenomatouspolyps: a meta-analysis. Gastroenterology. 2008;134: 388-395.
68. Paskett ED, Reeves KW, Rohan TE, et al. Association between cigarette smoking and colorectal cancer in the women's health initiative. J Natl Cancer Inst. 2007;99:1729-1735.
69. Hooker CM, Gallicchio L, Genkinger JM, Comstock GW, Alberg AJ. A prospective cohort study of rectal cancer risk in relation to active cigarette smoking and passive smoke exposure. Ann Epidemiol. 2008;18:28-35.
70. Asano TK, McLeod RS. Non steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev. 2004:CD004079.
71. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603-1613.
72. Wang YP, Wang Q, Gan T, Pan T, Yang JL. Non-steroidal anti-inflammatory agents for chemoprevention of colorectal polyps: a meta-analysis. Zhonghua Nei Ke Za Zhi. 2004;43:10-12.
73. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885-895.
74. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873-884.
75. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674-1682.
76. Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007;146:376-389.
77. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol. 2007;25:3462-3468.
78. Hebert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev. 1998;7:653-659.
79. Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol. 1999;93: 880-888.
80. Beral V, Banks E, Reeves G, Appleby P. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat. 1999;4:191-210.
81. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999;106: 574-582.
82. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 2002;288:321-333.
83. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299:1036-1045.
84. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:58-66.
85. Norrelund N, Norrelund H. Colorectal cancer and polyps in patients aged 40 years and over who consult a GP with rectal bleeding. Fam Pract. 1996;13: 160-165.
86. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91:434-437.
87. Mandel JS, Church TR, Bond JH, et al. The effect of fecal screening on the incidence of colorectal cancer. N Engl J Med. 2000;343:1603-1607.
88. Weller D, Coleman D, Robertson R, et al. The UK colorectal cancer screening pilot: results of the second round of screening in England. Br J Cancer. 1007;97:1601-1605.
89. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg. 2008;95:1029-1036.
90. Burch JA, Soares-Weiser K, St John DJ, et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen. 2007;14:132-137.
91. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:135-144.
92. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99:1462-1470.
93. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82-90.
94. Smith A, Young GP, Cole SR, Bampton P. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer. 2006;107: 2152-2159.
95. Fraser CG, Matthew CM, Mowat NA, Wilson JA, Carey FA, Steele RJ. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. Lancet Oncol. 2006;7:127-131.
96. Fraser CG, Mathew CM, Mowat NA, Wilson JA, Carey FA, Steele RJ. Evaluation of a card collection-based faecal immunochemical test in screening for colorectal cancer using a two-tier reflex approach. Gut. 2007;56:1415-1418.
97. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570-1595.
98. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351:2704-2714.
99. Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM. Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer. AHRQ Technology Assessment Program. Agency for Health Research and Quality; 2007.
100. Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med. 2002;346:311-320.
101. Traverso G, Shuber A, Olsson L, et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet. 2002;359:403-404.
102. Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 2001;93:858-865.
103. Itzkowitz SH, Jandorf L, Brand R, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2007;5:111-117.
104. Haug U, Brenner H. New stool tests for colorectal cancer screening: a systematic review focusing on performance characteristics and practicalness. Int J Cancer. 2005;117:169-176.
105. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149: 441-450.
106. Schroy PC III, Lal S, Glick JT, Robinson PA, Zamor P, Heeren TC. Patient preferences for colorectal cancer screening: how does stool DNA testing fare? Am J Manag Care. 2007;13:393-400.
107. Imperiale TF, Glowinski EA, Lin-Cooper C, Larkin GN, Rogge JD, Ransohoff DF. Five year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med. 2008;359:1218-1224.
108. UK Flexible Sigmoidoscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet. 2002;359:1291-1300.
109. Segnan N, Senore C, Andreoni B, et al. Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"-SCORE. J Natl Cancer Inst. 2002;94:1763-1772.
110. Weissfeld JL, Schoen RE, Pinsky PF, et al. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst. 2005;97:989-997.
111. Kerr J, Day P, Broadstock M, Weir R, Bidwell S. Systematic review of the effectiveness of population screening for colorectal cancer. N Z Med J. 2007; 120:U2629.
112. Segnan N, Senore C, Andreoni B, et al. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology. 2007;132:2304-2312.
113. Thiis-Evensen E, Hoff GS, Sauar J, Majak BM, Vatn MH. The effect of attending a flexible sigmoidoscopic screening program on the prevalence of colorectal adenomas at 13-year follow-up. Am J Gastroenterol. 2001;96:1901-1907.
114. Senore C, Segnan N, Bonelli L, et al. Predicting proximal advanced neoplasms at screening sigmoidoscopy. Dis Colon Rectum. 2004;47:1331-1340.
115. Lewis JD, Ng K, Hung KE, et al. Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systematic review and meta-analysis of screening colonoscopy. Arch Intern Med. 2003;163:413-420.
116. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326:653-657.
117. Levin TR, Farraye FA, Schoen RE, et al. Quality in the technical performance of screening flexible sigmoidoscopy: recommendations of an international multisociety task group. Gut. 2005;54:807-813.
118. Macafee DA, Scholefield JH. Antagonist: population based endoscopic screening for colorectal cancer. Gut. 2003;52:323-326.
119. Zubarik R, Ganguly E, Benway D, Ferrentino N, Moses P, Vecchio J. Procedure-related abdominal discomfort in patients undergoing colorectal cancer screening: a comparison of colonoscopy and flexible sigmoidoscopy. Am J Gastroenterol. 2002;97:3056-3061.
120. McLeod RS. Screening strategies for colorectal cancer: a systematic review of the evidence. Can J Gastroenterol. 2001;15:647-660.
121. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:132-141.
122. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G. The Norwegian colorectal cancer prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol. 2003;38:635-642.
123. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001;345:555-560.
124. Verne JE, Aubrey R, Love SB, Talbot IC, Northover JM. Population based randomized study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing. BMJ. 1998;317:182-185.
125. Rasmussen M, Fenger C, Kronborg O. Diagnostic yield in a biennial Hemoccult- II screening program compared to a once-only screening with flexible sigmoidoscopy and Hemoccult-II. Scand J Gastroenterol. 2003;38:114-118.
126. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997;112:594-642.
127. Rockey DC, Paulson E, Niedzwiecki D, et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet. 2005;365:305-311.
128. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med. 2000;343:162-168.
129. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003;124:544-560.
130. Winawer SJ, Zauber AG, O'Brien MJ, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Work group. N Engl J Med. 1993;328: 901-906.
131. Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut. 2001;48:812-815.
132. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150:1-8.
133. Rembacken BJ, Fujii T, Cairns A, et al. Flat and depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the UK. Lancet. 2000;355:1211-1214.
134. Sosna J, Sella T, Sy O, et al. Critical analysis of the performance of doublecontrast barium enema for detecting colorectal polyps > or = 6 mm in the era of CT colonography. AJR Am J Roentgenol. 2008;190:374-385.
135. Ballinger AB, Anggiansah C. Colorectal cancer. BMJ. 2007;335:715-718.
136. Soetikno RM, Kaltenbach T, Rouse RV, et al. Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA. 2008;299:1027-1035.
137. Singh H, Turner D, Xue L, Targownik LE, Bernstein CN. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA. 2006;295:2366-2373.
138. Tárraga López PJ. Cáncer colorrectal en Albacete impacto de un cribado mediante sangre oculta en Heces. Universidad Autónoma de Madrid; 1996.
139. Dai Z, Xu YC, Niu L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol. 2007;13:4199-4206.
140. Inoue T, Murano M, Murano N, et al. Comparative study of conventional colonoscopy and pan-colonic narrow-band imaging system in the detection of neoplastic colonic polyps: a randomized, controlled trial. J Gastroenterol. 2008;43:45-50.
141. Adler A, Pohl H, Papanikolaou IS, et al. A prospective randomised study on narrow-band imaging versus conventional colonoscopy for adenoma detection: does narrow-band imaging induce a learning effect? Gut. 2008;57:59-64.
142. Kaltenbach T, Friedland S, Soetikno R. A randomised tandem colonoscopy trial of narrow band imaging versus white light examination to compare neoplasia miss rates. Gut. 2008;57:1406-1412.
143. Brenner H, Chang-Claude J, Seiler CM, Sturmer T, Hoffmeister M. Does a negative screening colonoscopy ever need to be repeated? Gut. 2006;55:1145-1150.